Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule II - Valuation and Qualifying Accounts

v3.25.0.1
Schedule II - Valuation and Qualifying Accounts
 12 Months Ended
Dec. 28, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation And Qualifying Accounts
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS
(in thousands)
Description Balance at beginning of period Charged to costs and expenses Deductions Balance at end of period
December 28, 2024
Allowance for sales returns $ 420  $ 5,185  $ 5,307  $ 298 
Allowance for credit losses 421  —  200  221 
Valuation allowance - deferred tax assets 137,252  18,853  —  156,105 
December 30, 2023
Allowance for sales returns $ 572  $ 5,552  $ 5,704  $ 420 
Allowance for credit losses 363  112  54  421 
Valuation allowance - deferred tax assets 118,136  19,116  —  137,252 
December 31, 2022
Allowance for sales returns $ 547  $ 6,562  $ 6,537  $ 572 
Allowance for credit losses 504  6  147  363 
Valuation allowance - deferred tax assets 99,958  18,178  —  118,136